Immune checkpoints TIM-3 and LAG-3 can affect anti-tumour responses by inhibiting lymphocyte activity; however, NK cells in the MPE of MPM patients showed high TIM-3 and LAG-3 expression [45], meaning that TIM-3 and LAG-3 are likely to provide new opportunities for targeted MPE therapies. This evidence concerns the gene LAG3 and neoplasm.